Sodium glucose co-transporter 2 inhibitors in heart failure therapy

Turk Kardiyol Dern Ars. 2020 Apr;48(3):330-354. doi: 10.5543/tkda.2020.74332.
No abstract available

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Benzhydryl Compounds / adverse effects
  • Benzhydryl Compounds / pharmacology*
  • Benzhydryl Compounds / therapeutic use
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diastole / drug effects
  • Diuresis / drug effects
  • Female
  • Glucosides / adverse effects
  • Glucosides / pharmacology*
  • Glucosides / therapeutic use
  • Glycosuria / chemically induced
  • Heart Failure / drug therapy*
  • Heart Failure / prevention & control
  • Heart Failure / psychology
  • Heart Ventricles / drug effects
  • Heart Ventricles / physiopathology
  • Hospitalization / statistics & numerical data
  • Humans
  • Kidney Failure, Chronic / prevention & control
  • Male
  • Middle Aged
  • Mortality / trends
  • Myocardium / metabolism
  • Natriuresis / drug effects
  • Physical Endurance / drug effects
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Sodium-Glucose Transporter 2 Inhibitors / adverse effects
  • Sodium-Glucose Transporter 2 Inhibitors / pharmacology*
  • Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
  • Walk Test / methods

Substances

  • Benzhydryl Compounds
  • Glucosides
  • Sodium-Glucose Transporter 2 Inhibitors
  • dapagliflozin
  • empagliflozin